- Molecular NamePiperazine
- SynonymN/A
- Weight88.1515
- Drugbank_IDDB00592
- ACS_NO110-85-0
- Show 3D model
- LogP (experiment)-1.5
- LogP (predicted, AB/LogP v2.0)-1.18
- pka5.7, 9.8 (20°)
- LogD (pH=7, predicted)-3.68
- Solubility (experiment)1010 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)1.06
- LogSw (predicted, AB/LogsW2.0)888.21
- Sw (mg/ml) (predicted, ACD/Labs)1000.0
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds0
- TPSA24.06
- StatusFDA approved
- AdministrationN/A
- PharmacologyPiperazine is an anthelminthic especially useful in the treatment of partial intestinal obstruction caused by Ascaris worms, which is a condition primarily seen in children. Piperazine hydrate and piperazine citrate are the main anthelminthic piperazines.
- Absorption_value0.0
- Absorption (description)Rapidly absorbed from the gastrointestinal tract
- Caco_20.0
- Bioavailability0.0
- Protein binding65.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAbout 25% is metabolized in the liver. Piperazine is nitrosated to form N -mononitrosopiperazine (MNPz) in gastric juice, which is then metabolized to N-nitroso-3-hydroxypyrrolidine (NHPYR).
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include muscle fatigue, seizures, and difficulty breathing.
- LD50 (rat)N/A
- LD50 (mouse)LD50=5300 mg/kg